In April 2014 we launched the Shionogi Growth Strategy 2020 (SGS2020). SGS2020 sets our vision to grow as a drug discovery-based pharmaceutical company through clear priorities and focused resourcing, growth led by FIC and LIC compounds, and continued improvement of business operations.
In May 2016, we announced the rolling plan for FY2018, with targets of 125B yen of ordinary income and 15% of ROE. We aim to achieve our SGS2020 final-year targets for ordinary income and ROE two years early. As a result, in October 2016, we updated our FY2020 vision and targets accordingly.
＊1 First in Class (FIC) : Innovative medicines with particularly high novelty and usability that can change the existing therapeutic paradigm significantly
＊2 Last in Class (LIC) : Unrivaled medicines with clear superiority over others with the same mechanism of action